AstraZeneca PLC (AZN)vsTG Therapeutics Inc (TGTX)
AZN
AstraZeneca PLC
$182.85
+0.18%
HEALTHCARE · Cap: $286.68B
TGTX
TG Therapeutics Inc
$42.86
-0.38%
HEALTHCARE · Cap: $6.59B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 8530% more annual revenue ($60.44B vs $700.35M). TGTX leads profitability with a 65.9% profit margin vs 17.2%. AZN appears more attractively valued with a PEG of 1.52. TGTX earns a higher WallStSmart Score of 68/100 (B-).
AZN
Buy62
out of 100
Grade: C+
TGTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.6%
Fair Value
$220.34
Current Price
$182.85
$37.49 discount
Margin of Safety
-46.8%
Fair Value
$19.63
Current Price
$42.86
$23.23 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
Every $100 of equity generates 113 in profit
Keeps 66 of every $100 in revenue as profit
Revenue surging 69.6% year-over-year
Earnings expanding 300.0% YoY
Attractively priced relative to earnings
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
Expensive relative to growth rate
Trading at 9.5x book value
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : TGTX
The strongest argument for TGTX centers on Return on Equity, Profit Margin, Revenue Growth. Profitability is solid with margins at 65.9% and operating margin at 17.0%. Revenue growth of 69.6% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Bear Case : TGTX
The primary concerns for TGTX are PEG Ratio, Price/Book, Free Cash Flow.
Key Dynamics to Monitor
AZN profiles as a mature stock while TGTX is a growth play — different risk/reward profiles.
TGTX carries more volatility with a beta of 1.68 — expect wider price swings.
TGTX is growing revenue faster at 69.6% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
TGTX scores higher overall (68/100 vs 62/100), backed by strong 65.9% margins and 69.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
TG Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?